RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health. The firm pursues evidence-based investing across public and private markets and provides hands-on support to portfolio companies, including through its Raven healthcare incubator. It relies on deep research via its TechAtlas knowledge engine to identify opportunities and guide value creation from early-stage ideas to commercialization. Since its inception, the firm has deployed capital across multiple rounds and has built a portfolio of hundreds of companies, backed by an ongoing effort to advance drugs, medical devices, diagnostics, and biotech tools. RA Capital manages substantial assets and seeks to invest across stages—from seed to growth—often taking leading roles or co-investing and participating in governance to support management teams. The firm emphasizes impact in healthcare and planetary health, aiming to translate bold ideas into durable improvements in patient care and public health.

OrbiMed is a global healthcare investment firm, founded in 1989, that invests across the healthcare sector including biopharmaceuticals, medical devices, diagnostics, digital health, and healthcare services. It manages private equity, venture capital, and public equity investments, and provides financing solutions such as private debt and royalty monetization to support the development of new therapies and medical technologies. With a broad, globally distributed team, OrbiMed operates across multiple markets and provides strategic resources to companies from early-stage to growth, aiming to advance scientific innovation and improve patient outcomes.

Invus is a global investment firm with more than four decades of experience partnering with entrepreneurs to transform industries. Since 1985 it has built a patient, long-term capital base and aligns incentives with management to support lasting value creation. The firm manages substantial evergreen capital and operates offices in New York, London, Paris, and Hong Kong, enabling private equity investments, co-investments, and selective opportunities worldwide. It pursues a flexible, non-formulaic approach and focuses on minority and selective control investments across sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education, and medical devices. Invus emphasizes hands-on partnership, strategic guidance, and durable relationships, partnering with market-leading management teams to back growth through private transactions and syndicated financings, with a long-term orientation and capital structures designed to sustain portfolio companies as they scale.

Samsara BioCapital is a Palo Alto-based investment firm founded in 2016 that specializes in biotechnology and healthcare. The firm seeks to invest in biotechnology companies across the United States, with a focus on developing transformative therapeutics. It emphasizes collaboration among scientists, physicians, drug developers, and business leaders to advance innovative medicines. As a registered investment adviser and principal investment firm, Samsara BioCapital provides investment advisory services and pursues opportunities to support entrepreneurs in turning ideas into therapies. The company aims to foster biotech innovation by partnering with ambitious teams and supporting approaches that bring meaningful new treatments to patients.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, with offices in Asia. It operates a multi-strategy platform spanning venture capital, growth equity, private equity including buyouts, and public equity, and invests across biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm focuses on opportunities in the United States and China and maintains a track record of backing healthcare companies through multiple funding stages, including IPOs and strategic acquisitions. Assets under management are reported in the mid-to-high billions, approximately 5.8 to 6.1 billion, across several funds.

The European Innovation Council is a Europe-based organization that funds and accelerates deep technology startups and research. It supports top innovators and researchers and co-invests with private investors in early-stage ventures with ESG impacts, complementing private capital. The EIC operates programs such as the EIC Accelerator for equity investment and Business Acceleration Services, as well as EIC Prizes, to help breakthrough technologies reach the market. It fosters a deep tech ecosystem through thematic portfolios, data insights, and community dialogue, aiming to translate science into practical solutions across sectors including transport, mobility, and defence. Founded in 2018 and headquartered in Brussels, the council seeks to scale high-potential innovations and drive tangible impact across Europe.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines in the healthcare sector. It manages a private portfolio of investments and supports companies developing better treatment options for patients, including opportunities in private and public entities led by entrepreneurs. With teams in Palo Alto and New York City, the firm emphasizes rigorous scientific evaluation and portfolio management to accelerate breakthroughs in pharmaceutical solutions and health technology across the United States and Europe.

New Enterprise Associates is a global venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in the United States, India and China. The firm invests in technology and healthcare companies across all stages, from seed through IPO, with a broad sector focus that includes software, consumer technology, medical devices, life sciences, healthcare information technology, energy technology and related areas. NEA partners with founders to provide capital, domain expertise and strategic support for product development and market expansion, helping navigate changing economic environments. The firm maintains a track record of backing a large number of portfolio companies, with more than 210 IPOs and over 360 acquisitions.

ARCH Venture Partners is a Chicago-based venture capital firm with offices in Seattle that concentrates on life sciences and science-driven startups. Founded in 1986, it partners with scientists and entrepreneurs to bring innovations to market by providing capital, strategic guidance, and access to networks across the company’s lifecycle. The firm emphasizes translational work from academic research and national laboratories, and has raised more than $3 billion across multiple funds and invested in more than 150 companies, highlighting a hands-on approach to catalyzing discovery and execution in the life sciences sector.

Forbion is a global venture capital firm based in Naarden, Netherlands, specializing in investments in biotech, life sciences, and sustainable technologies. With two decades of experience, it backs both early-stage and growth-stage companies across Europe and North America, providing capital and strategic guidance to help translate scientific advances into therapies, diagnostics, and related health tech. The firm maintains a multi-fund platform and emphasizes responsible investing, including environmental, social, and governance considerations. Forbion collaborates with portfolio companies to support development and commercialization of innovative products that address human health and planetary health needs.

Deep Track Capital is a Greenwich, Connecticut-based venture capital firm focused on the biotechnology and life sciences sectors. It invests in public and pre-IPO biotechnology companies and emphasizes partnering with management teams, offering time, expertise, and a broad network in addition to capital. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, providing strategic guidance and resources to portfolio companies.

Logos Capital is an investment firm based in San Francisco that focuses on biotechnology. Founded in 2019, the company combines data analytics with scientific and clinical expertise to identify transformative therapies and opportunities in healthcare. Its multidisciplinary team spans biotechnology, medicine, and data science, and it uses a proprietary Logos Analytics platform to model clinical data, informing diligence and investment decisions. Logos Capital seeks long-term value by providing capital and strategic guidance to companies advancing innovative therapies, applying rigorous risk management and comprehensive analysis of clinical, regulatory, operational, and commercial factors. The firm evaluates opportunities across private and public biotechnology companies, aiming to generate meaningful returns through disciplined research and evidence-based investing.

Deerfield Management is a New York-based healthcare investment firm that advances human health through investment, research, and philanthropy. It manages investment strategies across public and private markets in biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, and healthcare services, and supports early-stage innovation through strategic partnerships and dedicated facilities that foster scientific research and drug discovery. The firm operates a philanthropic foundation focused on education, healthcare access, and initiatives aimed at improving health outcomes.

Versant Ventures is a global healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco, with offices in Canada, the United States, and Europe. It invests across the healthcare sector at all stages, with emphasis on discovery and development of novel therapeutics, including pharmaceuticals, biotechnology and medical devices. The firm combines investment, operating and scientific expertise to support portfolio companies with a hands-on, company-building approach. It manages over five and a half billion dollars in assets and has backed more than 65 portfolio companies that have achieved acquisitions or IPOs. Versant maintains in-house scientific teams and partnerships with more than 30 academic institutions to operate its Discovery Engines, a model aimed at launching biotech companies founded by academics. The firm operates from six locations globally to identify and nurture early-stage biotechnology companies with disruptive potential.

Sofinnova Partners is an independent venture capital firm based in Paris, France, founded in 1972, that invests in life sciences from seed to growth stages. It backs start-ups, corporate spin-offs and occasionally turnaround situations, focusing on biopharmaceuticals, biotech, medical devices, digital medicine, and related healthcare and sustainability innovations. The firm acts as a lead or cornerstone investor and frequently serves as the first institutional investor in Series A rounds, taking board seats and supporting portfolio companies from formation through exit to drive long-term value.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in early-stage investments in biotechnology and life sciences, with additional focus on technology companies. It partners with life science entrepreneurs to translate scientific discoveries into medicines and related diagnostics, often leading seed or Series A rounds and providing strategic guidance and board involvement. Founded in 1980, Atlas Venture has organized multiple funds and operates with dedicated Life Sciences and Technology teams to manage portfolio companies across the United States and Europe. Its portfolio emphasizes biopharmaceuticals, therapeutics, and medical technologies, along with software and data-driven technologies that support life science commercialization.

SR One is the corporate venture capital arm of GlaxoSmithKline and operates as a transatlantic biotechnology venture firm that invests globally in emerging life science companies pursuing innovative science to significantly improve medical care. Founded in 1985, it is based in Redwood City, California, with a London presence that provides geographic reach and regional expertise. The firm uses a back-and-build investment approach, partnering with founders to back companies with strong fundamentals, clear development plans, and novel approaches to disease treatment, to accelerate the translation of scientific breakthroughs into medicines. Since inception, SR One has invested about 800 million in more than 180 companies.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It focuses on seed through early-stage investments and selected later-stage opportunities in life sciences and information technology across the United States and Europe. In life sciences, it backs clinical-stage pharmaceutical products, biotechnology, biopharmaceuticals, therapeutic drugs and medical technology platforms addressing unmet medical needs, with initial investments typically in the low millions and total commitments in the tens of millions; the firm often requires a board seat when leading or co-leading early rounds. In information technology, it supports product-oriented IT, enterprise software, service-provider software and telecommunications infrastructure across development stages. Sofinnova collaborates with entrepreneurs to secure initial funding, build teams, win customers and navigate acquisitions and IPOs, leveraging domain expertise to help portfolio companies scale globally. It does not invest in healthcare services, diagnostics, nutraceuticals or tool-kit ventures.

Omega Funds is a Boston-based venture capital firm focused on investing in life sciences and healthcare companies across North America and Western Europe. Founded in 2004, the firm targets opportunities in oncology, immunology, rare diseases, precision medicine, digital health, cybersecurity, and software-as-a-service, providing capital and strategic support to entrepreneurs and founders. With emphasis on early-stage and growth-oriented opportunities, Omega Funds leverages an experienced team, a broad industry network, and a track record of helping portfolio companies advance products to patients and achieve strategic exits through public listings or acquisitions. The firm positions itself as a value-added investor, aligning scientific advancement with business development to drive meaningful clinical and commercial outcomes in the life sciences space. It operates as a registered investment adviser with international exposure across North America and Western Europe.

SOSV is a global venture capital firm that backs deep-tech startups through multi-stage investments and hands-on programs. It focuses on pre-seed and early-stage funding across healthcare, AI, robotics, hardware, and cross-border software, and supports founders with intensive mentorship, prototyping facilities, and access to a broad investor network to accelerate product development and fundraising toward Series B. The firm operates dedicated deep-tech facilities, including IndieBio, renamed SOSV SF & NY, and HAX in Newark, providing laboratory and engineering space, and maintains a global footprint with offices in New York, Newark, San Francisco, Silicon Valley, Pune, Shenzhen, and Tokyo. SOSV emphasizes long-term founder relationships and program-driven growth, backed by a substantial portfolio and capital deployed across multiple regions.

EcoR1 Capital is a San Francisco-based venture capital firm focused on supporting early-stage biotechnology companies developing innovative therapies. The firm seeks to back entrepreneurs driving therapeutic innovation and positions itself as a strategic partner to navigate drug discovery and development, leveraging scientific curiosity and a deep biotech background to identify valuable opportunities in biotech and help advance new medicines.

HBM Healthcare Investments is a Switzerland-based investment company founded in 2001 that focuses on the healthcare sector. It manages a globally diversified portfolio of investments in private and public healthcare companies, spanning human medicine, biotechnology, medical technology and diagnostics. The firm adopts a venture capital style approach and operates with a broad geographic footprint, seeking value creation through investments across the healthcare landscape.

Commodore Capital is a New York-based venture capital firm focused on biopharmaceuticals. Founded in 2019, the firm concentrates on early-stage companies developing innovative therapies, with emphasis on genetic medicines and cellular therapies, during a period of rapid scientific advancement translating into clinical breakthroughs. It aims to be a supportive partner to smaller biopharmaceutical companies as they develop and deliver new medicines to patients globally.

Boxer Capital is a biotechnology investment firm and the corporate venture capital arm of Tavistock Group, based in San Diego and founded in 2005. It invests in public and private biotechnology and life sciences companies across the drug development lifecycle, with an emphasis on precision medicine. The firm employs a research-driven, bottom-up due diligence process grounded in scientific, clinical, and regulatory perspectives to identify opportunities that aim to advance patient care and drive medical innovation.

Kurma Partners is a Paris-based private equity and venture capital firm established in 2009 that concentrates on healthcare and biotechnology investments across Europe, providing capital from early stages through development and growth. The firm focuses on financing therapeutic and medical innovations and maintains close collaborations with leading academic research institutions and hospitals to translate discoveries into medicines and medical devices. It manages a suite of funds, including Kurma Biofund I, Kurma Biofund II, Kurma Biofund III, Kurma Diagnostics and Kurma Growth Opportunities Fund, and partners with other investors to support companies from creation to expansion.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with an emphasis on early-stage drug discovery and long-term value creation. Founded in 2007, it supports companies from seed financing to later-stage development through an edge-to-edge investment approach across multiple funds, and it prioritizes deep scientific principles, hands-on mentoring for CEOs, and building strong, scientifically driven teams. Over its two-decade history, The Column Group has nurtured numerous biotech ventures and delivered substantial returns for its partners, while typically investing about $15–$30 million per deal in the United States across healthcare, oncology, drug discovery, and related sectors.

Merck is a global biopharmaceutical company focused on developing medicines and vaccines across multiple therapeutic areas, with a strong emphasis on oncology and immunology. Its portfolio includes an immuno-oncology platform led by Keytruda and a broad vaccine business, including vaccines for pediatric diseases such as Gardasil. The company prioritizes research and development, clinical trials, and patient access programs, while pursuing innovative collaborations and responsible manufacturing. Merck emphasizes sustainability and social responsibility through initiatives like Merck for Mothers and supports global health through philanthropy and funding programs. With a worldwide presence, Merck conducts R&D, manufacturing, and commercial activities to improve patient outcomes and address unmet medical needs.

Yuan Sheng Venture Capital is a Suzhou-based early and growth-stage healthcare investment firm anchored in the bioBAY ecosystem with global reach. Since its founding in 2013, it has invested in more than 200 life sciences companies across four core areas—new drug discovery, medical devices, diagnostics and precision medicine, and healthcare services—with nineteen portfolio companies listed on HKEX or the STAR Market. The firm is repeatedly recognized as one of China’s top medical health venture funds and operates a team of seasoned investors and global scientific advisers. By leveraging bioBAY resources and a network of over sixty invested enterprises, Yuan Sheng provides post-investment management and value-added services to help portfolio companies grow and reach milestones.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

Mission BioCapital is a life science venture capital firm that backs early-stage biotechnology and health science startups. Founded in 2009 and based in Cambridge, Massachusetts, with an office in San Francisco, the firm leverages a long-standing leadership team and a broad network to provide hands-on mentorship, strategic guidance, and resources such as shared laboratory space to portfolio companies. It emphasizes collaboration, innovation, and support for founders from diverse backgrounds, helping startups advance through research, development, and early commercial stages in the life sciences sector.

Pontifax Venture Capital is a healthcare-focused venture capital firm headquartered in Herzliya, Israel. It invests in transformative life sciences technologies across development stages, including pharmaceutical and biotechnology companies as well as medical devices, with a global reach and a particular emphasis on Israel. The firm seeks opportunities worldwide, providing portfolio companies with strategic guidance, capital markets expertise, and M&A savvy to help translate science into commercial success. Pontifax emphasizes hands-on involvement, networking, and active partnership to help early-stage ideas mature into growth-stage companies and to build leadership in the life sciences sector.

MPM BioImpact is a biotechnology-focused investment firm based in Boston that builds and funds companies transforming patient outcomes through drug development. With more than 30 years of experience, it invests in both private and public companies across various stages of the drug development process, spanning early to late-stage programs and across the biotechnology, healthcare, and life sciences sectors in the United States. The firm supports portfolio companies with leadership, expertise, and strategic guidance, collaborating with experienced individuals and academic institutions. Its portfolio includes Aktis Oncology, Orna Therapeutics, Reunion Neuroscience, and argenx, among others, reflecting a focus on innovative therapies that aim to translate scientific breakthroughs into life-saving medicines.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. The firm specializes in seed- and early-stage investments in life sciences, healthcare, and related technologies, with a portfolio spanning biopharmaceuticals, medical technology, and research instruments. It maintains a presence in Boston in addition to its San Francisco headquarters and pursues two primary strategies: venture capital investments in early-stage private companies typically seeking Series A financing, and public equity investments in select biotech and life science firms. 5AM Ventures emphasizes hands-on support, partnering with academics and entrepreneurs to build proof-of-concept data and to advance clinical and commercial milestones. Through its focus on healthcare and life sciences, the firm aims to advance next-generation therapies, diagnostics, and tools that address unmet medical needs.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments across technology and healthcare, with interest in AI, biotechnology, fintech, data analytics, cybersecurity, cloud and software, and related life sciences sectors. The firm supports startups in the United States, with a strong presence in Silicon Valley and New York, and has a history of backing notable technology and healthcare companies such as Apple Computer, Intel, Illumina, Athenahealth, Gilead Sciences, DoubleClick, Endeca, Nest, SlideShare and Tudou. Venrock pursues exits through acquisitions and IPOs and partners with entrepreneurs to build enduring companies.

Ally Bridge Group is a private investment firm established in 2013 and based in New York with a global footprint that includes Hong Kong, China, the United States and Europe. The group concentrates on healthcare and life sciences, investing across private and public markets in venture, growth, and select buyout opportunities in biopharmaceuticals, medical devices, diagnostics, and related technologies. It supports portfolio companies through board-level engagement and strategic acquisitions and leverages a global network to help translate scientific advances into commercial products. With more than 80 investments and over $2 billion deployed as of 2026, Ally Bridge Group pursues high impact innovations that improve patient care, empower physicians, and reduce healthcare costs.

Pivotal bioVenture Partners is a San Francisco–based venture capital firm focused on life sciences, including therapeutics, medical devices, diagnostics, and related platforms. Founded around 2017, the firm invests in privately held companies across North America and Europe, and maintains a China presence to support opportunities in Greater China. The team combines venture investing experience with drug discovery, development, and company-building expertise to back early- through late-stage ventures and to provide strategic guidance. The firm operates globally with offices in San Francisco, Shanghai, and Hong Kong, and is affiliated with Nan Fung Life Sciences, reflecting a broader platform that supports transformative therapies and healthcare innovations.

Catalio Capital Management is a New York-based investment company focusing on the full lifecycle of innovative healthcare investments across private, public, and credit markets. As of October 1, 2025, it manages about $2 billion in assets and employs over 40 professionals across New York City, Washington, DC, and London, supported by a network of more than 45 Venture Partners with equity interests. The firm pursues strategies across private equity, structured opportunities, public equities, and co-investments, and maintains a portfolio spanning drugs, AI-enabled technologies, devices, and diagnostics. It has a track record of IPOs, mergers and acquisitions, and loan repayments, and emphasizes proprietary deal flow generated by its network of scientist-entrepreneurs associated with life sciences.

Abingworth is an international life sciences investment firm founded in 1973. It collaborates with life sciences entrepreneurs to translate scientific ideas into health-improving products, investing across all development stages from start-ups to publicly traded companies in all life sciences sectors. Based in London with offices in Menlo Park and Boston, it manages over $1 billion and has invested in 142 life science companies, completing 60 IPOs and 40 mergers and acquisitions.

Medicxi is a life sciences–focused venture capital firm formed by the former Index Ventures life sciences team in 2016. Based in London with additional presence in Geneva and Jersey, it backs seed through late‑stage companies across Europe that pursue therapeutics, drug development, biotechnology and healthcare solutions. The firm supports discovery through clinical development, emphasizing novel therapies and platform innovations in areas such as vaccines and other biotech programs.

Aisling Capital is a New York-based venture capital and growth-investment firm specializing in healthcare and life sciences, focusing on mid-to-late stage opportunities in biopharmaceuticals, diagnostics, and related health technologies across the United States and Western Europe. Founded in 2000, the firm supports companies developing novel therapies and health products through capital and strategic guidance, leveraging extensive healthcare industry experience to help advance development and commercialization.

Khosla Ventures is a venture capital firm based in Menlo Park, California, that funds and supports technology companies across stages and sectors, including artificial intelligence, healthcare, climate tech, digital health, and consumer technology. It provides capital and strategic guidance to help startups develop innovative products, scale operations, and build enduring businesses, with an emphasis on science-driven, high-impact ventures and unconventional ideas. Founded by Vinod Khosla, the firm seeks to back companies addressing large, underserved markets and to contribute hands-on support beyond funding.

venBio Partners is a venture capital firm focused on life sciences investments in the United States, spanning early to late stages. It typically leads investments and constructs syndicates and teams to advance portfolio companies. From inception, the firm considers potential acquisition partners, aiming to position companies with strong IP, chemistry, manufacturing, and clinical trial readiness, including indication, trial design, endpoints, powering, and regulatory considerations. venBio backs teams developing novel therapeutics for unmet medical needs and emphasizes proactive collaboration with industry leaders to maximize impact. The firm has supported nine portfolio companies resulting in seven FDA approvals, and manages nearly $2 billion in committed capital. It operates from offices in San Francisco and Seattle and seeks to maximize the value of portfolio companies while fostering relationships with potential acquirers.

Alumni Ventures is a venture capital firm that broadens access to venture and private market investments for accredited investors, including alumni networks, by enabling co-investment alongside leading VC firms. It offers investment funds, investing clubs, portfolio opportunities, and educational resources through its AV Academy, and provides support to startup founders. The firm emphasizes transparency with access to due diligence materials and live discussions, and seeks to build a diversified portfolio through collaborative investing. Headquartered in Manchester, New Hampshire, it operates with offices in New York, Boston, Menlo Park, Chicago, London and Tokyo to reach a broad investor base.

Longitude Capital is a Menlo Park, California-based venture growth and private equity firm focused on biotechnology, medical technology, and health solutions. Founded in 2006, the firm backs both privately held and publicly traded life sciences companies through a range of structures, including traditional venture investments, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity-linked instruments. Its strategy centers on building a balanced portfolio of clinical-stage and commercial-stage assets that are clinically de-risked and offer attractive risk-adjusted returns within three to five years. The firm leverages a broad industry network and proprietary research to identify new opportunities and works with portfolio companies to optimize value.

Lumira Ventures is a North American life sciences venture capital firm with offices in Toronto, Montreal, Vancouver and Boston. It partners with entrepreneurial management teams to build biotechnology, biopharmaceuticals, medical devices, digital health and consumer health companies that address significant unmet needs. The firm targets investments in Canada and the United States, typically writing checks in the multi-million-dollar range and supporting portfolio companies with financings, access to partners, and market development through active board participation. Since the firm’s inception, it has invested in more than 100 healthcare companies and maintains a portfolio of active investees across Canada and the United States, reflecting a focus on transforming patient care and healthcare delivery.

Third Rock Ventures is a venture capital firm founded in 2007 and headquartered in Boston, Massachusetts, with additional offices in San Francisco. It focuses on life sciences and healthcare, including biotechnology, medicine, drugs, devices, diagnostics, therapeutics, and related information technology. The firm invests in early-stage and startup companies with high growth potential and transformative potential in healthcare. It typically leads rounds and pursues active involvement in portfolio companies, including strategic collaborations and hands-on management where appropriate, to help build companies from concept to market. Its approach emphasizes developing patient-centered solutions and advancing therapies and technologies across multiple therapeutic areas, including oncology, autoimmune diseases, and gene therapy. The firm generally concentrates its investments in U.S.-based life sciences companies and seeks to partner with entrepreneurs to accelerate development of medicines, diagnostics, and medical technologies.

IMM Private Equity is an independent private equity firm based in Seoul, South Korea, specializing in growth capital, significant minority investments, and middle-market buyouts. It pursues Korea- and Asia-focused opportunities, taking an active role in portfolio companies to drive value through strategic guidance and operational improvements across sectors such as manufacturing, information technology, internet, leisure, retail, and cultural contents.

Ysios Capital is a leading independent Spanish venture capital firm that provides private equity financing to early- and mid-stage life sciences and human healthcare companies developing novel therapies, diagnostics and medical devices. Founded in 2008 and based in Donostia-San Sebastián, the firm manages hundreds of millions of euros in assets and operates across Europe and North America. It backs biotech ventures across pharmaceuticals, diagnostics, medical devices, digital health and related platforms, often taking board seats to support product development and fundraising. The objective is to advance clinical and commercial milestones and pursue exits through public offerings or mergers and acquisitions.

Longwood Fund is a Boston-based venture capital firm focused on science-based healthcare companies. Founded in 2010, it invests in novel medical solutions that arise from top-tier research, commonly affiliated with institutions such as Harvard and MIT. The firm emphasizes value-added partnerships and active involvement, with partners sometimes taking co-founding leadership roles to help accelerate portfolio companies from laboratory discovery toward patient impact.